Baxter Healthcare Corporation and Alpha Therapeutic Corporation offer a new brand of product in augmentation therapy - Aralast™ Alpha1-Proteinase Inhibitor.

It is with great pride and excitement that Baxter Healthcare Corporation and Alpha Therapeutic Corporation offer the Alpha-1 community a new brand of product in augmentation therapy - Aralast™ Alpha₁- Proteinase Inhibitor (human).

Aralast™ is indicated as a chronic replacement therapy for patients who have clinically evident emphysema as a result of having inherited a deficiency of Alpha₁-proteinase inhibitor.

Baxter offers this therapeutic with a firm commitment to making current supplies of Aralast™ available immediately. As a leading developer of plasma-derived biopharmaceutical therapies, we plan to gradually increase the supplies of Aralast™ and bring lasting change to the Alpha-1 community - one day, one person at a time.

I encourage you to visit www.baxter.com/aralast/assoc to review the features of Aralast™. You will see that is has both an excellent efficacy and safety profile and is shown to be highly tolerable. Aralast™ has a multi-step purification process that includes two viral treatment steps - solvent detergent treatment for rapid inactivation of lipid-enveloped viruses and nanofiltration for reduction of non-lipid-enveloped viral agents.

Another benefit I would like to point out is Baxter's selection of reputable specialty pharmacies to provide Aralast™. These specialty pharmacies offer comprehensive care from a team of experienced homecare pharmacists, nurses and client representatives. In addition, physicians and patients will benefit from support in treatment plan monitoring, insurance coverage and patient education offered by these specialty pharmacies.

On behalf of the entire Baxter team, we look forward to serving the Alpha-1 community and building on our long and successful history of providing critical therapies for life threatening conditions.